Nearly half of Ultrio plus NAT non-discriminated reactive blood donors were identified as occult HBV infection in South China

BMC Infect Dis. 2019 Jul 3;19(1):574. doi: 10.1186/s12879-019-4215-9.

Abstract

Background: Blood donor plasma samples were detected by the Ultrio Plus NAT system for HBV, HCV and HIV-1 in Shenzhen blood center, China. Reactive samples underwent further discriminatory testing of a single virus by the same methodology. A large number of cases of non-discriminated reactive (NDR) donors were found, leaving potential risk of transmitting HBV if not deferrals. This study identified those non-discriminated samples.

Methods: The NDR plasma samples from blood donation screening were detected and classified by additional molecular and serological tests. Molecular characterizations of DNA+ NDR were determined by sequencing analysis.

Results: A number of 259 (0.21%) NDR plasma samples from screening of 123,280 eligible blood donors were detected, which presented a higher rate (91.1%) of anti-HBc reactivity and nearly half (46.7%) of HBV DNA+ that classified as occult HBV infection (OBI). Most OBI strains were wild-type HBV, but some substitutions V168A, S174 N, V177A, Q129R/L/H, G145A/R in S region of genotype B (OBIB) and T47K/V/A, P49H/L, Q101R/H/K, S174 N, L175S, V177A, T118 M/R/K, G145R/A/K/E, R160K/N in S region of genotype C (OBIC) strains were identified in high frequency.

Conclusion: Nearly half of NDR blood samples were identified as OBI, in which a number of important mutations were detected. NDR donation might have potential risk for HBV transmission, but need to be further investigated.

Keywords: Blood safety; Molecular characterization; Non-discriminated reactive (NDR); Occult hepatitis B infection (OBI); Re-entry policy.

MeSH terms

  • Adult
  • Blood Donors*
  • China
  • Female
  • Genotype
  • HIV-1 / genetics
  • Hepacivirus / genetics
  • Hepatitis B / virology*
  • Hepatitis B Antibodies / blood
  • Hepatitis B Surface Antigens / blood
  • Hepatitis B virus / genetics*
  • Humans
  • Male
  • Mutation
  • Polymerase Chain Reaction / methods
  • Serologic Tests / methods

Substances

  • Hepatitis B Antibodies
  • Hepatitis B Surface Antigens